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The human metastasis-associated protein 1 (MTA1) is a constituent of the nucleosome-remodelling and -deacetylation complex. Its
expression has been correlated with the invasion and metastasis of epithelial neoplasms. To address the functional consequences of
MTA1 expression in pancreatic carcinoma cells, we have established PANC-1 pancreatic carcinoma cells that stably express MTA1 as
an enhanced green fluorescent fusion protein (EGFP–MTA1). Here, we demonstrate that heterologous expression of EGFP–MTA1
markedly enhanced the cellular motility and the invasive penetration of epithelial barriers by the cells. Expression of EGFP-MTA1 had
no effect on substrate-independent growth, but reduced substrate-dependent cell proliferation. In addition, the organisation of the
cytokeratin filament system and the localisation of the actin cytoskeleton-associated protein IQGAP1 were distinctly altered in
EGFP–MTA1-expressing cells. These results indicate that enhanced expression of MTA1 promotes the acquisition of an invasive,
metastatic phenotype, and thus enhances the malignancy of pancreatic adenocarcinoma cells by modulation of the cytoskeleton.
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The metastasis-associated gene 1 (mta1) was identified by
differential cDNA screening using cell lines derived from highly
metastatic mammary adenocarcinomas (Toh et al, 1994), and
expression of metastasis-associated protein 1 (MTA1) correlated
with the invasive and metastatic potential of cultured mammary
tumour cells (Toh et al, 1994, 1995). Enhanced expression of
MTA1 mRNA was also found in a variety of other human
cancerous tissues and carcinoma cell lines, for example in
colorectal, gastric (Toh et al, 1997), or oesophageal (Toh et al,
1999) carcinomas and thymoma (Sasaki et al, 2001). Comparative
analyses revealed that MTA1 mRNA was differentially expressed in
nonmetastatic and metastatic tumours, thus pointing towards a
role of MTA1 in enhancing the metastatic potential of malignant
tumour cells (reviewed in Nicolson et al, 2003).
The MTA1 protein is a representative of the MTA1 family
highly conserved throughout evolution with 88% identities of
nucleotide and 96% identities of amino-acid sequences
between rat and human MTA1. Other members of this
protein family are MTA1-L1 (Futamura et al, 1999), MTA2 (Zhang
et al, 1999), and MTA3 (Simpson et al, 2001). Homologues of
MTA1 and MTA2 were found in Caenorhabditis elegans and
Drosophila (Herman et al, 1999; Solari et al, 1999; Erkner et al,
2002).
The mta1 gene has been mapped to the centre of a 1.6Mb region
of human chromosome 14q 31.2 (Martin et al, 2001) and encodes a
protein of 715 amino acids with a calculated molecular mass of
80.8kDa (Toh et al, 1994; Nawa et al, 2000). Sequence analysis
revealed that the human MTA1 protein contains a proline-rich
region (aa: 697–705), which matches the consensus sequence for
the src homology 3 domain (SH3)-binding site (Toh et al, 1995;
Nawa et al, 2000). A second potential SH3-binding site is located
between amino acids 545 and 552. Other potential protein–protein
and protein–DNA interaction domains are: a putative GATA-like
zinc-finger-motif, a bromo-adjacent-homology domain (BAH
domain), a SWI3, ADA2, N-CoR, and TFIIIB DNA-binding domain
(SANT domain), several putative phosphorylation sites for
tyrosine kinases, protein kinase C, and casein kinase 2, and three
putative nuclear localisation sequences (Nawa et al, 2000; reviewed
in Nicolson et al, 2003). Although MTA1 and the related protein
MTA2 were recently identified as constituents of the nucleosome-
remodelling and deacetylation complex (NuRD) (Xue et al, 1998;
Zhang et al, 1999), the exact role of MTA proteins in the NuRD
complex, especially in chromatin remodelling and transcriptional
repression, is unknown. Mazumdar et al (2001) have reported that
activation of the heregulin/human epidermal growth-factor
receptor 2 (HER2) signalling pathway in oestrogen-receptor-
positive breast cancer cells stimulated MTA1 expression. The
augmented expression contributes to enhanced histone deacetylase
activity, inhibition of oestrogen-receptor element-driven gene
transcription, and progression to an invasive phenotype. More-
over, it has been reported that MAT1 (me ´nage a ´ trios 1), an
assembly/targeting factor for cyclin-dependent kinase-activating
kinase (CAK), is an MTA1-binding protein (Talukder et al, 2003).
The results reported in the latter study suggest that MTA1 might
inhibit CAK-induced oestrogen receptor transactivation function
by recruiting histone deactylase.
Pancreatic adenocarcinoma is a highly aggressive malignant
tumour, which is characterised by pronounced invasiveness and
rapid progression. Although molecular pathological and genetic
studies have presented a framework of the cellular alterations that
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yare associated with pancreatic adenocarcinoma, most of the data
comprise only correlative links to the underlying cancer biology
(Bardeesy and DePinho, 2002). In pancreatic cancer tissues, the
MTA1 mRNA expression levels seem to be correlated with lymph
node metastasis, whereas in established pancreatic carcinoma cell
lines MTA1 mRNA levels were not correlated with the cells’
propensity to metastasise (Iguchi et al, 2000). Thus no definitive
role of MTA1 in the progression of pancreatic cancer has yet been
established.
In the present study, we have examined whether enhanced
expression of MTA1 in itself modifies the malignant phenotype of
pancreatic carcinoma cells. We describe that expression of an
enhanced green fluorescent protein (EGFP)–MTA1 fusion protein
in the human pancreatic carcinoma cell line PANC-1 resulted
in nuclear localisation of the protein and caused a marked
enhancement of cellular motility and invasion through epithelial
barriers and, at the same time, a reduction of cell proli-
feration. Furthermore, MTA1-expressing PANC-1 pancreatic
carcinoma cells exhibited distinct changes in arrangement
and localisation of cytoskeletal proteins, such as keratins and
IQGAP1. The results demonstrate that enhanced expression of
MTA1 triggers the development of motile, invasive pancreatic
carcinoma cells by altering the organisation of the cellular
cytoskeleton.
MATERIALS AND METHODS
Materials
[
32P]dCTP (5000Cimmol
 1) was obtained from Amersham
Biosciences (Freiburg, Germany). 4,6-Diamidino-2-phenylindole
dihydrochloride (DAPI) was from Sigma (Taufkirchen, Germany).
Primary antibodies: monoclonal anti-GFP (clones 7.1 and 13.1)
(Roche Diagnostics, Mannheim, Germany), monoclonal anti-b-
actin (clone AC-15) (Sigma, Taufkirchen, Germany), polyclonal
anti-human pancreatic polypeptide (DakoCytomation, Hamburg,
Germany), monoclonal anti-human cytokeratin 18 (DakoCytoma-
tion, Hamburg, Germany), monoclonal anti-IQGAP1 (Zymed, San
Francisco, CA, USA). Secondary antibodies: peroxidase-conjugated
goat anti-mouse IgG, alkaline phosphatase-conjugated anti-mouse
IgG (Sigma, Taufkirchen, Germany); Cy3-conjugated goat anti-
mouse (Jackson ImmunoResearch Laboratories, Hamburg, Ger-
many). All other chemicals were of analytical grade and obtained
from standard suppliers.
Cell lines and culture conditions
Human pancreatic carcinoma cell lines PANC-1 (CRL 1469), BxPC-
3 (CRL 1687), and MiaPaCa-2 (CRL 1420) were obtained from
American Type Culture Collection ATCC (Manassas, VA, USA).
PaTu 8988t and PaTu 8988s were kindly provided by Dr HF Kern
(Marburg, Germany) (Elsasser et al, 1992). Cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
L-glutamine (2mM), penicillin–streptomycin (100IUml
 1–
0.1mgml
 1), and 10% (vv
 1) fetal calf serum. Cell culture media
and supplements were from Invitrogen (Karlsruhe, Germany).
Cells were incubated at 371C in a humidified atmosphere of 90%
air and 10% CO2. Serum starvation was performed in DMEM
without supplements. Liposome-mediated DNA transfection was
carried out with 30ml DMRIE-C reagent (Invitrogen, Karlsruhe,
Germany) and 15mg DNA per 10cm dish of subconfluent cells
according to the manufacturer’s instructions. Enhanced green
fluorescent protein- and EGFP–MTA1-expressing cell clones were
obtained by cultivation of cells in medium supplemented with
1.5mgml
 1 G418 (Invitrogen, Karlsruhe, Germany). Selected,
green fluorescent cell clones were continuously kept in this
selection medium.
Northern blot analysis
Total RNA was extracted using the RNeasy Midi Kit from Qiagen
(Hilden, Germany) according to the manufacturer’s instructions.
For Northern blot analysis, 30mg of total RNA was separated by
denaturing formaldehyde–agarose gel electrophoresis (1% (wv
 1)
agarose) and transferred onto Hybond N nylon membranes
(Amersham Biosciences, Freiburg, Germany), as described in
Menke et al (1997). Blots were hybridised with [
32P]dCTP-labelled
rat MTA1 cDNA and the amount of transferred mRNA was
analysed by rehybridising blots with [
32P]dCTP-labeled mouse b-
actin cDNA. [
32P]dCTP labelling was performed using the Multi-
prime DNA labelling system (Amersham Biosciences, Freiburg,
Germany).
Cloning of a pEGFP-C2/MTA1 expression plasmid
A pBluescript SK( ) vector containing the coding region of the rat
MTA1 cDNA in the BamHI restriction site was kindly provided by
Dr A Nawa (University of Texas, Houston, TX, USA). The insert
was ligated in frame as a BamHI fragment into the pEGFP-C2
vector (Clontech BD Biosciences, Heidelberg, Germany). The
sequence was verified by DNA sequencing.
Cell lysate preparation and protein determination by
immunoblot analysis
The expression of EGFP–MTA1 protein in transfected cells was
analysed in cell lysates by immunoblotting. Approximately 5 10
6
cells in a 10cm dish were washed with ice-cold phosphate-buffered
saline (PBS) (140mM NaCl, 2.7mM KCl, 8mM Na2HPO4, 1.5mM
KH2PO4, pH 7.2), and homogenised in 500ml of RIPA buffer
(50mM Tris/HCl, pH 7.2, 150mM NaCl, 10mM MgCl2,1 %( vv
 1)
Triton X-100, 0.5% (wv
 1) sodium deoxycholate, 0.5% (wv
 1)
SDS, 10mgml
 1 aprotinin, 10mgml
 1 leupeptin, and 0.1mM
phenylmethylsulphonyl fluoride (PMSF)) by 10 strokes in a
glass–glass Dounce homogeniser. The suspension was cleared by
centrifugation in a benchtop centrifuge at 15800g for 15min at
41C and the protein concentration was determined by the
bicinchoninic acid assay (Pierce, Sankt Augustin, Germany), using
bovine serum albumin fraction V (BSA; 2mgml
 1) as a standard.
Cell lysates (130mg of protein) were separated on 10% SDS–
polyacrylamide gels and transferred onto nitrocellulose mem-
branes (Schleicher & Schuell, Dassel, Germany). Enhanced green
fluorescent proteins were detected by using anti-GFP and
peroxidase-conjugated secondary antibodies, and the ECL Western
Blotting Detection System (Amersham Biosciences, Freiburg,
Germany). Equal loading was controlled by reprobing the blot
with anti-b-actin and alkaline phosphatase-conjugated secondary
antibodies.
Growth and migration assays
Proliferation assays For proliferation assays, 2 10
3 cells were
seeded per well of a 12-well cell culture dish in DMEM
supplemented with 10% FCS. Every 48h, cells of two independent
wells were detached by trypsinisation and cell numbers were
determined using a haemocytometer chamber. Growth curves were
calculated by nonlinear regression analysis and doubling times
were determined for the exponential growth phase using the
GraphPad Prism 3.02 software (GraphPad Software, San Diego,
USA).
Soft agar assays Soft agar assays were performed as described in
Weisz et al (1999). Briefly, for one well of a six-well plate, 1 10
4
cells (in DMEM with 10% FCS) were mixed with 0.5ml of 0.34%
(wv
 1) agar and seeded onto 1.5ml of bottom agar containing
0.5% (wv
 1) agar in DMEM with 10% FCS. The upper agar layer
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371C and 10% CO2 and the medium was replaced every 48h.
Number and size of cell colonies were determined after incubation
periods of 14 and 28 days.
Migration assays To determine cell migration, 5 10
4 cells were
seeded in 500ml DMEM containing 10% FCS on top of noncoated
polyethylene terephthalate (PET) membranes of trans-well cell
culture inserts (12-well inserts, 8mm pore size; BD Biosciences,
Heidelberg, Germany). The bottom chamber was filled with 1.2ml
of DMEM. After 1h, mitomycin C (10mgml
 1; Sigma, Taufkirchen,
Germany) was added to the medium in the upper chamber to
inhibit cell proliferation. Cells were incubated for 2h. Thereafter,
cells in the upper chamber were washed with DMEM and
incubated in 400ml DMEM. The medium in the bottom chamber
was replaced by 1.2ml of DMEM with or without 10% FCS. After
24h, the cells were fixed in 4% (wv
 1) paraformaldehyde in PBS,
stained for 15min with Harris’ haematoxylin solution (Merck,
Darmstadt, Germany), and washed three times for 15min each in
2ml each of tap water. Cells that had remained on top of the
membrane were wiped away. Cells that had migrated to the bottom
side of the membrane were visualised under the microscope and
quantified by counting the number of cells in three randomly
chosen visual fields at 100-fold magnification.
Chorioallantoic membrane (CAM) invasion assay
The invasive potential of the cells was analysed using the CAM-
model previously described by Kunzi-Rapp et al (2001) with some
modifications. Briefly, cells (5 10
5 cells in 20ml DMEM) were
seeded into a silicone ring (5mm diameter) placed on the
chorioallantoic membrane of fertilised chicken eggs on day 5 of
the breeding protocol and incubated for another 6 days at 37.81C,
60% relative humidity. The chorioallantoic tissue area containing
the silicone ring was isolated, fixed with 4% (vv
 1) formaldehyde,
paraffin-embedded, and 4mm sections were transferred to micro-
scopic slides and stained with haematoxylin and eosin. For
immunohistochemistry, sections were mounted on poly-L-lysine-
coated slides and subsequently deparaffinised and rehydrated.
Antigen retrieval was carried out by heating in vapour for 20min
in 10mM citrate buffer, pH 6.0, and nonspecific binding sites were
blocked with 10% goat serum for 20min at room temperature.
Polyclonal antiserum against pancreatic polypeptide was applied at
a dilution of 1:100 according to the manufacturer’s protocol
(DakoCytomation, Hamburg, Germany). Antibodies were detected
using the Histostain-Plus streptavidin peroxidase staining proce-
dure with AEC chromogen/substrate reagent (Zymed, San
Francisco, CA, USA).
Immunofluorescence Staining
For immunofluorescence staining, 1 10
4 cells were seeded on
glass coverslips (13mm diameter) and grown to about 90%
confluence. After fixation with 4% (wv
 1) paraformaldehyde in
PBS, cell membranes were permeabilised for 15min with 0.2%
(vv
 1) Triton X-100 in PBS, and nonspecific binding sites were
blocked with 3% BSA (wv
 1) in PBS for 30min at 371C. Treatment
with the first antibody was performed at room temperature for
60min with anti-cytokeratin 18 and anti-IQGAP1 antibodies, each
diluted 1:100 in 0.2 % BSA (wv
 1) in PBS. Afterwards, the cells
were washed three times with PBS and incubated with Cy3-
conjugated anti-mouse IgG diluted 1:2000 in 0.2% BSA (wv
 1)i n
PBS for 30min at room temperature. Nuclei were stained for
15min at room temperature with DAPI (2mgml
 1 methanol). Cells
were rinsed with H2O and the coverslips were mounted by
inverting them into 10ml Mowiol (2.8g Mowiol 4-88, Hoechst
(Frankfurt am Main, Germany), 6g glycerol, 6ml H2O, 12ml of
200mM Tris/HCl, pH 8.5). Cells were examined with an inverse
IX70 fluorescence microscope (Olympus, Hamburg, Germany) and
images were recorded using a CCD camera and the analySIS 3.1
imaging system (Soft Imaging System, Mu ¨nster, Germany).
RESULTS
MTA1 mRNA expression in pancreatic carcinoma cell lines
To investigate the expression of MTA1 mRNA in different human
pancreatic carcinoma cell lines, Northern blot analysis was
performed using radiolabelled rat MTA1 cDNA for hybridisation.
As shown in Figure 1, MTA1 mRNAs of approximately 3.0
kilobases in size were present in all pancreatic carcinoma cell lines,
but at different expression levels. Since PANC-1 cells express only
low levels of endogenous MTA1 mRNA, we chose this cell line to
investigate the effects of heterologous MTA1 expression on the cell
biological properties of pancreatic carcinoma cells.
Subcellular localisation of EGFP–MTA1 in PANC-1 cells
For expression of exogenous MTA1 in PANC-1 cells, the cDNA of
rat MTA1 was cloned into a pEGFP-expression vector to obtain an
EGFP–MTA1 fusion protein. PANC-1 cells were transfected with
the vectors pEGFP or pEGFP–MTA1 and cell clones with stable
expression of the encoded proteins were selected by G418
treatment. Four of the cell clones expressing EGFP–MTA1 (named
MTA1-7, MTA1-8, MTA1-9, MTA1-16) were used for further
analysis. The EGFP-expressing PANC-1 cell clones EGFP-14 and
EGFP-21 served as controls. Figure 2 shows the results of a
fluorescence microscopical comparison of one EGFP-expressing
PANC-1 clone (EGFP-21) and two EGFP–MTA1-expressing clones
(MTA1-9 and MTA1-16). The images demonstrate that EGFP
proteins were homogeneously distributed in the cytosol and in the
nucleus, whereas EGFP–MTA1 fusion proteins showed a pre-
dominantly nuclear localisation (centre panels). The nuclear
localisation of EGFP–MTA1 was verified by costaining of nuclei
with 4,6-diamino-2-2-phenylindol (DAPI) (bottom panels). Similar
results were obtained for the PANC-1 clones EGFP-14 and EGFP–
MTA1-7 and MTA1-8 (data not shown). In additional experiments
(results not shown), the localisation of MTA1 in the nucleus was
Figure 1 Northern blot analysis of MTA1 mRNA expression in
pancreatic carcinoma cell lines. Total RNA was prepared from PANC-1,
BxPC-3, MiaPaCa-2, PaTu 8988s, and PaTu 8988t pancreatic carcinoma
cells, fractionated (30mglane
 1) by denaturating formaldehyde–agarose
(1% (wv
 1)) gel electrophoresis and transferred onto a nylon membrane.
Hybridisation was performed with a radiolabelled MTA1 cDNA probe
(upper panel). To assess equal loading of the analysed RNA, the blot was
rehybridised with a radiolabelled b-actin cDNA fragment (lower panel).
The positions of the 28S and 18S ribosomal RNA bands are indicated.
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analysis.
Effects of EGFP–MTA1 on cell growth
Expression of EGFP–MTA1 in PANC-1 cells led to a significant
inhibition of cell proliferation, as shown in Table 1. The EGFP-
expressing cell clone EGFP-21 exhibited the shortest doubling
time, approximately 37h, closely corresponding to the doubling
time observed for the parental PANC-1 cells previously determined
to be approximately 36h (Giehl et al, 2000). Compared to control
cells, EGFP–MTA1-expressing cells from the four independent
clones, MTA1-7, MTA1-8, MTA1-9, and MTA1-16, displayed an
increase in the doubling time ranging between 16 and 50%.
To determine whether substrate-independent growth of PANC-1
cells (Giehl et al, 2000) was altered by expression of the EGFP–
MTA1 protein, soft agar assays were performed on clone MTA1-16
and the control clone EGFP-21. Determination of the average
colony size at day 28 showed no difference between the two cell
clones. The sizes of colonies formed by EGFP-21 control cells and
EGFP–MTA1-expressing MTA1-16 cells were 219720 and
19979mm (means7s.e.m, n¼3), respectively. Since the numbers
of colonies formed during the incubation time also showed no
obvious differences, we conclude that overexpression of MTA1
does not alter the capacity of PANC-1 to grow in a substrate-
independent manner.
Influence of MTA1 on cell migration and invasion
The migratory behaviour of EGFP- and EGFP–MTA1-expressing
PANC-1 cells was analysed using trans-well migration assays. Both
types of PANC-1 cells share a similar size and typically display a
diameter of approximately 20mm. Cells were seeded on top of a
porous membrane and migration was analysed in the absence or
presence of FCS as chemoattractant in the lower compartment.
Figure 3A shows that, in the absence of FCS, expression of EGFP–
MTA1 in MTA1-9 and MTA-16 cells caused an approximately 3.3-
and 4.2-fold increase in cell migration, respectively, as compared to
EGFP-21 cells. Addition of FCS to the lower compartment increased
the number of migrating cells in control and EGFP–MTA1-
expressing cells. Specifically, migration of EGFP-21 cells was
increased by 2.1-fold in the presence of FCS in comparison to
untreated EGFP-21 cells. In the presence of FCS, expression of
EGFP–MTA1 in MTA1-9 and MTA-16 PANC-1 cells caused a 2.4-
fold and 3.2-fold increase compared to the corresponding EGFP-21
cells. Thus, under both conditions, that is with and without FCS as
chemoattractant, EGFP–MTA1-expressing cells exhibited an ap-
proximately three-fold enhanced cell motility as compared to
controls. The immunoblots shown in Figure 3B demonstrate that
both EGFP–MTA1 cell clones expressed approximately the same
amount of EGFP–MTA1 protein. Thus, at least in the two cell
clones analysed, there was no apparent correlation between EGFP–
MTA1 expression and enhancement of motility and invasiveness.
To examine the effect of EGFP–MTA1 expression on the
invasive potential of PANC-1 cells, their ability to invade through
the outer epithelial cell layer of the CAM of fertilised chicken eggs
into the underlying mesenchymal tissue was examined. Figure 3C
depicts photomicrographs of CAM tissue sections 6 days after
inoculation of EGFP-expressing EGFP-21 control cells and EGFP–
MTA1-expressing MTA1-9 and MTA1-16 cells onto the CAM.
Enhanced green fluorescent protein-expressing control cells were
exclusively located on top of the outer epithelial membrane of the
CAM and did not penetrate through this boundary (panel a,
arrow). In striking contrast, cells expressing EGFP–MTA1 broke
through the epithelium membrane and invaded into the under-
lying mesenchyme (panels c–f). In some sections, formation of
solid tumours was clearly evident (panels e and f, arrows).
Furthermore, the CAM was markedly thickened around this area of
infiltration. To ascertain that these tumours were indeed derived
from exogenous PANC-1-cells, immunostaining of the tissue with
antibodies directed against pancreatic polypeptide was performed.
The results confirmed that EGFP-21 control cells did not penetrate
through the outer epithelium of the CAM (b, arrow), and that the
tumours in the mesenchymal tissue were indeed of pancreatic
origin, that is were formed by EGFP–MTA1-expressing cells.
MTA1-induced changes in the arrangement of cytoskeletal
proteins
The acquisition of a motile, invasive phenotype is accompanied by
a change in the architecture and composition of the cytoskeleton
and cell–cell adhesion complexes. Previous publications have
Figure 2 Subcellular localisation of EGFP–MTA1. Subconfluent EGFP-
and EGFP–MTA1-expressing PANC-1 cells were fixed and stained with
DAPI to visualise cell nuclei. Images in the top panel represent phase
contrast images of PANC-1 cells expressing either EGFP alone (EGFP-21)
or the EGFP–MTA1 fusion protein. Cells from two clones expressing
EGFP–MTA1 (MTA1-16, MTA1-9) are shown. Images in the middle and
bottom panels represent fluorescent micrographs of the same cells showing
the localisation of EGFP and EGFP–MTA1, and DAPI-stained nuclei. Bars:
20mm.
Table 1 Proliferation of PANC-1 cells expressing EGFP or EGFP–MTA1
Cell clone
Doubling time (h)
(7s.e.m, n¼3)
Increase in doubling time (%)
compared to EGFP-21 cells
EGFP-21 37.471.7 —
MTA1-7 43.671.4 16% (Po 0.01, t-test)
MTA1-8 52.970.9 40% (Po 0.001, t-test)
MTA1-9 56.072.7 50% (Po 0.001, t-test)
MTA1-16 48.471.4 28% (Po 0.001, t-test)
PANC-1 cells expressing either EGFP (EGFP-21) or EGFP–MTA1 (MTA1-7, MTA1-8,
MTA1-9, MTA1-16) were grown in DMEM supplemented with 10% FCS. Cell growth
was determined by counting the cells every 48h over a period of 12 days. Growth
curves were calculated by nonlinear regression analysis for exponential growth and
the average doubling times were determined using the GraphPad Prism 3.02
software. The means 7s.e.m of three independent experiments are presented.
Statistical analysis was performed using the Student’s t-test.
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filament proteins cytokeratins and vimentin in various tumour
cells, which seems to correlate with their metastatic potential
(Hendrix et al, 1996; Thomas et al, 1999). To address the question
whether expression of EGFP–MTA1 altered the expression of these
proteins, immunoblot analyses were performed. Both cytokeratins
and vimentin were found to be expressed in parental PANC-1 cells
and the total amount of these proteins did not change upon
expression of EGFP or EGFP–MTA1 (data not shown). To examine
whether expression of EGFP–MTA1 affects the subcellular
distribution and organisation of cytokeratin filaments, immuno-
fluorescence analyses were performed on EGFP-14 control cells
and MTA1-9 cells using an antiserum reactive against human
cytokeratin 18 (Figure 4, top panels). The results revealed that the
extensive filamentous network composed of cytokeratin 18-
containing filaments was much more diffuse, and that the long
filaments seemed to be dissolved in MTA1-expressing cells as
compared to EGFP-expressing controls. Quantitative analysis
revealed that only 20% of EGFP–MTA1-expressing PANC-1 cells
exhibited a well-organised cytokeratin filament system, while
approximately 80% of EGFP-expressing or parental PANC-1 cells
exhibited a well-organised cytokeratin filament system (data not
shown). These changes were not only apparent upon staining of
cells with a cytokeratin 18, but were also evident after staining with
a pankeratin antibody. The organisation of vimentin filaments was
not markedly altered (data not shown).
Another process involved in cell migration is the dynamic
rearrangement of cell–cell adhesion complexes and the actin
cytoskeleton. Localised disruption of E-cadherin-mediated cell–
cell adhesion sites was recently observed in invasive human colon
carcinoma cells (Shimao et al, 2002) and this disruption was
associated with relocalisation of IQGAP1, a Rac1/Cdc42 effector
molecule (Kuroda et al, 1998). Therefore, the subcellular distribu-
tion of IQGAP1 was studied by immunofluorescence analysis
(Figure 4, bottom panels). The results showed a marked increase in
membrane-localised IQGAP1 and a decrease in the cytoplasmic
IQGAP1 immunostaining in EGFP–MTA1-expressing MTA1-9
cells in comparison to EGFP-expressing EGFP-21 control cells.
Furthermore, IQGAP1 seemed to be enriched in membrane ruffles
and protrusions.
Figure 3 Stimulation of tumour cell migration and invasion by EGFP–MTA1. (A) Cell migration. PANC-1 cells (5 10
4 cellswell
 1) expressing either
EGFP (EGFP-21) or EGFP–MTA1 fusion protein (MTA1-9 and MTA1-16) were seeded in trans-well cell migration inserts (8mm pore size). The upper
chamber contained DMEM without supplements. The lower chamber was filled with either DMEM (empty bars) or DMEM supplemented with 10% FCS
(hatched bars). The incubation was carried on for 24h, and the cells were then fixed and stained with haematoxylin. Cells that had migrated to the bottom
side of the filters were counted in three randomly selected microscopic fields (magnification:  100) per filter. The fold-changes relative to the cell number
observed for control EGFP-expressing PANC-1 cells expressing in the presence of DMEM without serum are shown as means 7s.e.m of three independent
experiments. The stimulatory effect of augmented MTA1 expression on cell migration was statistically significant at a level of Po 0.05 both in the absence
and in the presence of 10% FCS, as determined by Kruskal–Wallis one-way analysis of variance. (B) PANC-1 cells expressing either EGFP (EGFP) or EGFP–
MTA1 (MTA-9, MTA-16) were homogenised in RIPA buffer and 130mg of protein were subjected to SDS–PAGE and immunoblotting. Immunoreactive
proteins were detected using antibodies reactive against EGFP and ECL detection system. To control for equal loading, the blot was reprobed with an
antibody reactive against b-actin. The positions of EGFP–MTA1, b-actin, and the molecular weight markers are shown. (C) Cell invasiveness. PANC-1 cells
expressing either EGFP (EGFP-21) or the EGFP–MTA fusion protein (MTA1-9, MTA1-16)( 5  10
5 cellsegg
 1) were grafted onto the chorioallantoic
membrane of fertilised chicken eggs on day 5 of the breeding protocol. After 6 days, the chorioallantoic membranes were removed, embedded in paraffin,
and cut into 4mm sections. The sections were then either stained with haematoxylin–eosin to assess cell morphology (left panel) or subjected to
immunostaining using antibodies reactive against pancreatic polypeptide to specifically identify PANC-1 pancreatic carcinoma cells (right panel). EGFP- or
EGFP–MTA1-expressing PANC-1 cells are indicated by arrows. Magnification:  200.
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In the present study, we have investigated the functional
consequences of stable heterologous expression of an EGFP–
MTA1 fusion protein in the human pancreatic carcinoma cell line
PANC-1. The results presented here demonstrate that expression
of EGFP–MTA1 (i) resulted in a nuclear localisation of the protein,
(ii) caused an attenuation of cell proliferation, but (iii) markedly
increased cell migration and invasion, and (iv) induced distinct
changes in the organisation of the cytokeratin filament system and
the localisation of cytoskeleton-associated proteins.
The nuclear localisation of EGFP–MTA1 in PANC-1 cells is in
agreement with the domain structure of MTA1 comprising a BAH
and a SANT domain, which have been found in proteins involved
in transcriptional regulation (Aasland et al, 1996; Callebaut et al,
1999). As shown in Table 1, expression of EGFP–MTA1 fusion
protein decreased the proliferation rate of PANC-1 pancreatic
carcinoma cells. This observation is in contrast to results
describing growth inhibition of MDA-MB-231 breast cancer cells
upon treatment with MTA1 antisense oligonucleotides (Nawa et al,
2000). However, neither overexpression of MTA1 nor inhibition of
MTA1 expression had any detectable effect on cell cycle
progression or proliferation of HaCaT keratinocytes (Mahoney
et al, 2002), MCF-7 (Mazumdar et al, 2001), or MDA-MB-435
breast cancer cells (Nawa et al, 2000). The reasons for these
divergent findings are currently unclear, but might be related to
differences in growth-regulating signalling pathways that are either
unrelated to or less dependent on MTA1 expression. Although
EGFP–MTA1-expressing PANC-1 cells proliferated slower when
cultured on plastic, the substrate-independent growth of PANC-1
cells was not markedly affected by the expression of EGFP–MTA1.
This could either mean that substrate-independent growth of
PANC-1 cells is independent of MTA-1 expression or that any
attenuation of this type of proliferation is compensated for by
another, growth-promoting mechanism. In contrast to the results
obtained here, stable expression of MTA1 in MCF-7 breast cancer
cells resulted in a markedly enhanced ability of these cells to grow
substrate-independently and to form large colonies in soft agar
(Mazumdar et al, 2001). While the reasons of this apparent
discrepancy are currently unknown, it seems clear that an increase
in cell proliferation is unlikely to be the basis of the enhanced
metastatic potential of pancreatic cancer cells with elevated MTA1
expression described by Iguchi et al (2000).
Metastatic cells exhibit an enhanced rate of cell migration, an
enhanced ability to penetrate epithelial layers, and an enhanced
tendency for invasive growth (Wells, 2000). The results of this
study show that cells expressing EGFP–MTA1 showed a markedly
enhanced cell motility. In addition, serum components acting as
chemoattractants further stimulated cell migration of EGFP–
MTA1-expressing PANC-1 cells, suggesting that the expression of
MTA1 accelerates the overall motility of PANC-1 cells. This
enhanced motile response was even more evident when the ability
to penetrate into a three-dimensional tissue was analysed. Thus,
only the EGFP–MTA1-expressing PANC-1 cells broke through the
CAM and formed solid tumours in the mesenchymal tissue of the
CAM. These results show that EGFP–MTA1-expressing PANC-1
cells have acquired the ability to penetrate an epithelial layer and
to successfully prevail against CAM cells in the underlying tissue.
Iguchi et al (2000) investigated the correlation between MTA1 gene
expression and metastatic potential of pancreatic cancer in
patients and of pancreatic cancer cell lines. Although MTA1
mRNA expression did not correlate with the metastatic potential in
the analysed pancreatic carcinoma cell lines, as evaluated by a liver
metastasis assay in nude mice, MTA1 mRNA expression levels in
pancreatic cancer tissues seemed to be correlated with the
occurrence of lymph node metastasis in the corresponding
patients. On the basis of their results, Iguchi et al suggest a
possible role for MTA1 in the progression of pancreatic cancer, in
particular with regard to giving rise to lymph node metastases.
Furthermore, a correlation between MTA1-expression, invasion,
and migration has recently been shown for immortalised
keratinocytes (Mahoney et al, 2002). Taken together, results in
the literature and our findings demonstrate that elevated MTA1
expression augments the capacity of epithelial cells for metastatic
dissemination.
How MTA1 promotes the more motile, invasive phenotype of
PANC-1 pancreatic carcinoma cells is currently unknown.
Modulation of cell shape by remodelling of the cytoskeleton and
alterations of cell surface adhesion molecules are prerequisites for
invasive growth (Wells, 2000). We could not detect any obvious
changes in the organisation of the tubulin or actin filament system
in adherent EGFP–MTA1-expressing cells (data not shown).
Interestingly, the cytoskeleton-associated protein IQGAP1 was
predominantly localised at the membrane of EGFP–MTA1-
expressing cells, whereas it showed a cytoplasmatic localisation
in the EGFP-expressing control cells. Membrane localisation of
IQGAP1 was previously found to be inversely correlated with the
Figure 4 Effect of MTA1 on the organisation of the intermediate
filament system and the localization of IQGAP1. Subconfluent PANC-1
cells expressing either EGFP (EGFP-14) or EGFP–MTA1 (MTA1-9) were
grown for 48h in DMEM supplemented with 10% FCS, fixed, and
immunostained as indicated with antibodies reactive against cytokeratin 18
or IQGAP1 followed by Cy3-conjugated second antibodies. Enhanced
green fluorescent protein fluorescence was visualised for control.
Membrane ruffles and protrusions are marked by arrows. Bars: 20mm.
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2001) and was observed in human colorectal carcinoma cells,
especially at the invasion front (Nabeshima et al, 2002), as well as
in human colon carcinoma cells following treatment with
heptocyte growth factor (HGF) (Shimao et al, 2002). IQGAP1 is
an actin- and Cdc42-binding protein (Erickson et al, 1997; Swart-
Mataraza et al, 2002) and it has also been shown to negatively
regulate the E-cadherin/catenin-based cell–cell adhesion by
dissociating a-catenin from the E-cadherin/catenin complex
(Fukata et al, 1999; Kuroda et al, 1998). Thus, translocation of
IQGAP1 to the plasma membrane and reduced cell–cell adhesion
as a consequence of heterologous EGFP–MTA1 expression might
be a reason for the observed enhanced cell motility and invasion.
In addition to IQGAP1 translocation, MTA1 induced changes in
the organisation of the cytokeratin system. PANC-1 cells express
different cytokeratins, such as the acidic cytokeratins 18 and 19
and the basic cytokeratin 8 (data not shown). These cytokeratins
are also found in ductal adenocarcinoma of the pancreas (Hoorens
et al, 1998). Expression of EGFP–MTA1 caused dissolution of the
distinctively structured filamentous cytokeratin network, giving
rise to a network of filiform bundles as well as aggregates at the cell
periphery (cf. Figure 4). Although cytokeratin filaments have been
considered to be relatively stable cytoskeletal structures, there is
increasing evidence for dynamic processes in cell migration,
cytokinesis, and apotosis (Goldman et al, 1999; Strnad et al, 2002,
and literature cited therein). Very little is known about the
molecular principles that govern the dynamics of cytokeratin
filament organisation, but phosphorylation of cytokeratins at
serine and threonine residues causes major rearrangements of the
filament structure in various cell types (Herrmann and Aebi, 2000;
Strnad et al, 2002). How EGFP–MTA1 remodels the cytokeratin
filament system in PANC-1 cells remains to be determined.
In summary, this study demonstrates that heterologous expres-
sion of EGFP–MTA1 facilitates the acquisition of an invasive,
metastatic phenotype of PANC-1 pancreatic carcinoma cells.
Enhanced expression of MTA1 might be of considerable im-
portance for the progression to malignancy of pancreatic
neoplasms.
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